CAMBRIDGE, Mass. & LAUSANNE, Switzerland–(BUSINESS WIRE)–Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced the expansion of an exclusive global collaboration agreement with Bristol Myers Squibb, focused on developing therapeutics for autoimmune diseases, to include Anokion’s lead antigen-specific drug candidate, KAN-101, for the treatment of celiac disease.
“We are excited to expand our relationship with Bristol Myers Squibb, which underscores the substantial therapeutic opportunity we believe our programs hold for people with autoimmune diseases who lack disease-modifying treatments today,” said John Hohneker, M.D., president and chief executive officer of Anokion. “Bristol Myers Squibb is an industry leader with significant capabilities across all phases of drug development. By expanding our agreement to encompass our celiac disease program, we are further ensuring that our novel discoveries have the resources needed to be fully prosecuted and reach as many patients as possible.”
Under the terms of the amended agreement, originally executed in 2016 with Celgene, now a Bristol Myers Squibb company, an undisclosed Amendment fee was paid to Anokion to include KAN-101 for the treatment of celiac disease in the exclusive global collaboration. Anokion is responsible for preclinical activities and Phase 1 clinical development of partnered programs, and Bristol Myers Squibb will fund subsequent trials and commercial activities at clinical proof-of-concept.
“We are intrigued by the opportunity to leverage this immune tolerization platform as a treatment for celiac disease, as well as multiple sclerosis,” said Rupert Vessey, Ph.D., M.A., B.M., B.Ch., F.R.C.P., D.Phil., executive vice president & president, research & early development, Bristol Myers Squibb. “We look forward to further collaborating with Anokion to bring potential new treatments to patients with autoimmune diseases.”
KAN-101 is currently being evaluated in a randomized, double-blind, placebo-controlled Phase 1 study, Assessment of KAN-101 in Celiac Disease (ACeD), that is designed to evaluate its safety and tolerability in patients with celiac disease on a gluten-free diet. Anokion anticipates reporting preliminary data from this first-in-human study later this year. In addition, ANK-700, Anokion’s second antigen-specific program, has completed IND-enabling studies and the company expects to initiate clinical development for the treatment of multiple sclerosis in the second half of 2020.
Anokion retains full control of its program focused on type 1 diabetes, as well as its research and development pipeline.
Anokion SA is a Swiss biotechnology company that aims to make a meaningful difference in the lives of patients suffering from autoimmune diseases by restoring normal immune tolerance. The company is focused on both prevalent and rare autoimmune diseases, including celiac disease, multiple sclerosis and type 1 diabetes. Anokion’s distinct approach leverages the company’s immune-based platform, which targets natural pathways in the liver to restore immune tolerance and address the underlying cause of autoimmune disease. For more information, please visit http://www.anokion.com/.